{
 "id": "epn1b3j62k",
 "slug": "tumor-infiltrating-lymphocyte-therapy",
 "title": "Tumor-infiltrating lymphocyte therapy",
 "updated": "2026-10-15",
 "topic_path": [
  {
   "id": "life",
   "label": "Life and health",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life"
  },
  {
   "id": "life.health",
   "label": "Human health and medicine",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health"
  },
  {
   "id": "life.health.medicines",
   "label": "Medicines and therapeutics",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines"
  },
  {
   "id": "life.health.medicines.biologics-mabs",
   "label": "Biologics, monoclonal antibodies, and biosimilars",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.biologics-mabs"
  }
 ],
 "geo": [
  {
   "id": "geo.nongeo.t1946.life.health.medicines.biologics-mabs",
   "label": "Non-geographic · 1946 to 2000: Biologics, monoclonal antibodies, and biosimilars",
   "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.biologics-mabs",
   "path": [
    {
     "id": "geo.nongeo",
     "label": "Non-geographic",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo"
    },
    {
     "id": "geo.nongeo.t1946",
     "label": "Non-geographic · 1946 to 2000",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946"
    },
    {
     "id": "geo.nongeo.t1946.life",
     "label": "Life and health",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life"
    },
    {
     "id": "geo.nongeo.t1946.life.health",
     "label": "Human health and medicine",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health"
    },
    {
     "id": "geo.nongeo.t1946.life.health.medicines",
     "label": "Medicines and therapeutics",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines"
    },
    {
     "id": "geo.nongeo.t1946.life.health.medicines.biologics-mabs",
     "label": "Biologics, monoclonal antibodies, and biosimilars",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.biologics-mabs"
    }
   ]
  }
 ],
 "excerpt": "Tumor-infiltrating lymphocyte (TIL) therapy is an autologous cell therapy for advanced solid cancer in which T cells from a patient's tumor are grown and reinfused.",
 "snippet": "Tumor-infiltrating lymphocyte (TIL) therapy is an autologous cell therapy for advanced solid cancer in which T cells from a patient's tumor are grown and reinfused.",
 "node": "life.health.medicines.biologics-mabs",
 "markdown": "# Tumor-infiltrating lymphocyte therapy\n\nTumor-infiltrating lymphocyte (TIL) therapy is an autologous adoptive cell therapy in which lymphocytes harvested from a patient's own tumor are expanded ex vivo and reinfused, after lymphodepleting chemotherapy, to treat advanced solid cancer. The infused product is a polyclonal T-cell population that recognizes multiple patient-specific tumor neoantigens (new antigens on tumor cells that immune cells recognize), which distinguishes it from single-antigen CAR-T and TCR-engineered products.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11005706/)</sup> The field reached a regulatory milestone in February 2024, when the FDA granted accelerated approval to lifileucel (Amtagvi), the first approved TIL product and the first cellular therapy approved for any solid tumor.<sup>[2](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma)</sup>\n\n| Key fact | Detail |\n|---|---|\n| Product delivered | Polyclonal, unmodified autologous T cells recognizing multiple patient-specific neoantigens<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11005706/)</sup> |\n| Pooled melanoma response | ORR 42% (95% CI 37–47%) across 18 single-arm cohorts<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC13437784/)</sup> |\n| Phase III result | ORR 49% vs 21% for ipilimumab; median PFS 7.2 vs 3.1 months<sup>[4](https://link.springer.com/article/10.1007/s40257-025-00957-5)</sup> |\n| Lifileucel pivotal trial | ORR 31.4% (8 complete, 40 partial responses); median PFS 4.1 months; median OS 13.9 months<sup>[5](https://jitc.bmj.com/content/10/12/e005755)</sup> |\n| Manufacturing | Centralized 22-day process; median resection-to-infusion 33 days; 94.7% of resected patients received an in-specification product<sup>[5](https://jitc.bmj.com/content/10/12/e005755)</sup> |\n| Conditioning | Cyclophosphamide 60 mg/kg daily × 2 days, fludarabine 25 mg/m² daily × 5 days, then IL-2 600,000 IU/kg up to 6 doses<sup>[6](https://www.fda.gov/media/176417/download)</sup> |\n| Regulatory status | FDA accelerated approval (Feb 2024); Health Canada conditional approval (Aug 2025); EMA application withdrawn (Jul 2025)<sup>[2](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma)</sup><sup> • </sup><sup>[7](https://link.springer.com/article/10.1038/s41416-026-03350-z)</sup> |\n\n## How it works\n\nTIL therapy transfers naturally occurring tumor-homing T cells rather than engineered ones. Because the product is polyclonal, it can target a multitude of patient-specific tumor neoantigens simultaneously, lowering reliance on any single antigen.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11005706/)</sup> Lymphodepletion before infusion is a key component of efficacy: it eliminates T regulatory cells and removes endogenous lymphocytes that would otherwise compete with the transferred cells for the homeostatic cytokines IL-7 and IL-15, allowing the infused population to expand.<sup>[8](https://www.nature.com/articles/nrc2355)</sup>\n\nSingle-cell tracking in melanoma shows what separates responders from non-responders. Responders' infusion products contained a higher fraction of CD8+ CD137+ tumor-reactive cells and delivered on average 31.8 billion inferred tumor-reactive cells, versus fewer than 1 billion in non-responders.<sup>[9](https://doi.org/10.1016/j.immuni.2024.08.014)</sup> Tumor-reactive clonotypes from responders also engrafted in post-treatment tumors far more often, linking persistence and homing of reactive clones to clinical response.<sup>[9](https://doi.org/10.1016/j.immuni.2024.08.014)</sup>\n\n## How it is done\n\nThe workflow runs from surgery to infusion over roughly five weeks<sup>[10](https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70526)</sup>:\n\n1. **Resection and transport.** A metastatic lesion of at least 1.5 cm diameter (typically 1.5–4 cm) is resected and shipped at 2–8 °C in sterile medium.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11005706/)</sup>\n2. **Pre-REP culture.** Tumor is minced into fragments (about 1 mm³) or enzymatically digested and cultured for 2–4 weeks in high-dose IL-2 (up to 6,000 IU/mL) to drive T-cell outgrowth.<sup>[11](https://pure.amsterdamumc.nl/ws/portalfiles/portal/139845125/Tumour-infiltrating-lymphocyte-therapy-for-patients-with-advanced-stage-melanoma.pdf)</sup><sup> • </sup><sup>[12](https://doi.org/10.1016/j.ccell.2024.06.015)</sup>\n3. **Rapid expansion protocol (REP).** A 14-day expansion with IL-2 (3,000 IU/mL), the anti-CD3 antibody OKT3, which stimulates the TCR/CD3 complex, and irradiated allogeneic feeder mononuclear cells yields on average \\( 5 \\times 10^{10} \\) cells (range \\( 5 \\times 10^{9} \\) to \\( 2 \\times 10^{11} \\)).<sup>[11](https://pure.amsterdamumc.nl/ws/portalfiles/portal/139845125/Tumour-infiltrating-lymphocyte-therapy-for-patients-with-advanced-stage-melanoma.pdf)</sup><sup> • </sup><sup>[12](https://doi.org/10.1016/j.ccell.2024.06.015)</sup>\n4. **Lymphodepletion.** [Cyclophosphamide](https://www.edgepedia.org/cyclophosphamide) 60 mg/kg IV daily for 2 days, followed by fludarabine 25 mg/m² IV daily for 5 days.<sup>[4](https://link.springer.com/article/10.1007/s40257-025-00957-5)</sup>\n5. **Infusion and IL-2 support.** The TIL product (median administered \\( 2.11 \\times 10^{10} \\) viable cells) is infused on day 0, followed by aldesleukin 600,000 IU/kg every 8–12 hours for up to 6 doses starting 3–24 hours after infusion.<sup>[6](https://www.fda.gov/media/176417/download)</sup> Patients are hospitalized, discharged about 14 days after infusion, and advised to stay within 30–50 miles of the center.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11005706/)</sup>\n\n## Origin\n\nThe lineage runs through the Surgery Branch of the US National Cancer Institute. A 1985 New England Journal of Medicine study by [Steven A. Rosenberg](https://www.edgepedia.org/steven-a-rosenberg), Michael T. Lotze, Linda M. Muul, and colleagues reported adoptive transfer of lymphokine-activated killer (LAK) cells with recombinant interleukin-2, the precursor approach TIL therapy built on.<sup>[13](https://doi.org/10.1056/nejm198512053132327)</sup> In 1986, Rosenberg, Paul Spiess, and Rene Lafreniere reported in Science the first demonstration in murine models that adoptive transfer of TIL could mediate regression of established tumors.<sup>[14](https://doi.org/10.1126/science.3489291)</sup>\n\nThe 1988 NEJM paper by Rosenberg and colleagues treated 20 metastatic melanoma patients with TIL plus IL-2 after a single cyclophosphamide dose: objective regression occurred in 9 of 15 IL-2-naive patients (60%) and 2 of 5 previously IL-2-treated patients (40%), in lung, liver, bone, skin, and subcutaneous sites, lasting 2 to more than 13 months.<sup>[15](https://doi.org/10.1056/nejm198812223192527)</sup> A 2002 regimen adding non-myeloablative cyclophosphamide plus fludarabine lymphodepletion, and the 2005 Journal of Clinical Oncology study by Mark E. Dudley, John R. Wunderlich, James C. Yang, and colleagues of adoptive transfer after non-myeloablative lymphodepletion, established the modern conditioning platform.<sup>[8](https://www.nature.com/articles/nrc2355)</sup><sup> • </sup><sup>[16](https://doi.org/10.1200/jco.2005.00.240)</sup> Rosenberg, James C. Yang, Richard M. Sherry, and colleagues reported durable complete responses in heavily pretreated melanoma in 2011<sup>[17](https://doi.org/10.1158/1078-0432.ccr-11-0116)</sup>, and Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, and colleagues showed in 2006 that genetically engineered lymphocytes could mediate cancer regression, the parallel TCR-engineered line.<sup>[18](https://doi.org/10.1126/science.1129003)</sup>\n\n## Variants\n\n**Young TIL** pools all fragment cultures from one patient directly into the REP, almost halving total ex vivo time; shorter culture preserves function, consistent with a 45-day threshold beyond which TIL functionality deteriorates.<sup>[19](https://mdpi-res.com/d_attachment/immuno/immuno-01-00012/article_deploy/immuno-01-00012.pdf?version=1625822468)</sup> In a meta-analysis, ex vivo pre-screened tumor-reactive TIL products showed pooled ORR 50% (95% CI 35–64%), young TIL 43%, and bulk TIL 36%.<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC13437784/)</sup>\n\n**Lifileucel (LN-144, Amtagvi)** is a ready-to-infuse, cryopreserved product based on the NCI method and optimized by Iovance Biotherapeutics: centralized 22-day manufacturing, cryopreservation at below −150 °C in 5% DMSO, and a 33-day harvest-to-infusion time.<sup>[4](https://link.springer.com/article/10.1007/s40257-025-00957-5)</sup><sup> • </sup><sup>[20](https://cdn.clinicaltrials.gov/large-docs/79/NCT02360579/Prot_000.pdf)</sup> Its pivotal phase 2 results were reported by Amod A. Sarnaik, [Omid Hamid](https://www.edgepedia.org/omid-hamid), Nikhil I. Khushalani, and colleagues in 2021.<sup>[21](https://doi.org/10.1200/jco.21.00612)</sup>\n\n**IL-2-free engineered TILs** are in early trials: OBX-115, engineered with acetazolamide-regulated membrane-bound IL-15, removes post-infusion IL-2, and GT201 carries constitutively active membrane-bound IL-15 with a reported 42.9% partial response rate in 7 phase 1 patients.<sup>[4](https://link.springer.com/article/10.1007/s40257-025-00957-5)</sup>\n\n**Manufacturing innovations** include a closed, automated [CliniMACS Prodigy](https://www.edgepedia.org/clinimacs-prodigy) process that selects CD137+ tumor-reactive TILs and completes expansion in 16 days, one of the shortest processes described.<sup>[22](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1483254/full)</sup> [Combination](https://www.edgepedia.org/combination) with checkpoint blockade is another variant: first-line pembrolizumab plus lifileucel produced an ORR of 63.6% (14/22), supporting the phase III TILVANCE-301 trial.<sup>[7](https://link.springer.com/article/10.1038/s41416-026-03350-z)</sup>\n\n## Applications\n\nIn melanoma, a meta-analysis of 18 single-arm cohorts found a pooled ORR of 42% (95% CI 37–47%); durable complete responses have persisted 37–82+ months in some series.<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC13437784/)</sup> In the randomized phase III M14TIL trial, TIL gave ORR 49% (95% CI 38–60) versus 21% for ipilimumab, median PFS 7.2 versus 3.1 months, and median OS 25.8 versus 18.9 months, with fewer serious adverse events (15% vs 27%).<sup>[4](https://link.springer.com/article/10.1007/s40257-025-00957-5)</sup><sup> • </sup><sup>[7](https://link.springer.com/article/10.1038/s41416-026-03350-z)</sup>\n\nFor lifileucel, the pooled 153-patient analysis showed IRC-assessed ORR 31.4% (95% CI 24.1–39.4%), median PFS 4.1 months, and median OS 13.9 months, with 41.7% of responses maintained at least 18 months.<sup>[5](https://jitc.bmj.com/content/10/12/e005755)</sup> The FDA label reports ORR 31.5% among 73 patients treated at the recommended dose, with 56.5%, 47.8%, and 43.5% of responders maintaining response at 6, 9, and 12 months.<sup>[2](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma)</sup>\n\nBeyond melanoma: LN-145 TIL in advanced cervical cancer achieved an ORR of 44%, earning FDA breakthrough therapy designation.<sup>[23](https://www.mdpi.com/2072-6694/14/17/4160)</sup> In NSCLC, a phase 1 trial of TIL with nivolumab in 20 patients progressing on nivolumab produced 3 confirmed responses among 13 evaluable patients, with two complete responses ongoing at 1.5 years.<sup>[24](https://pubmed.ncbi.nlm.nih.gov/34385708/)</sup> A multi-tumor phase I/II trial produced confirmed partial responses in head-and-neck cancer and [cholangiocarcinoma](https://www.edgepedia.org/cholangiocarcinoma).<sup>[25](https://jitc.bmj.com/content/jitc/9/10/e003499.full.pdf)</sup> [Melanoma](https://www.edgepedia.org/melanoma) responds best largely because expanding tumor-reactive TILs from non-melanoma solid tumors is difficult and is the primary limiting factor for efficacy in those diseases.<sup>[12](https://doi.org/10.1016/j.ccell.2024.06.015)</sup>\n\nOn manufacturing feasibility, lifileucel was manufactured for 179 of 187 resected patients (95.7%) and within specification for 177 (94.7%).<sup>[5](https://jitc.bmj.com/content/10/12/e005755)</sup> Published sources report that lifileucel (Amtagvi) has a $515,000 list price for a single treatment; published reviews describe manufacturing as complex, expensive, and difficult to scale beyond select centers.<sup>[10](https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70526)</sup><sup> • </sup><sup>[27](https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma)</sup>\n\n## Limitations and alternatives\n\nThe roughly 5-week procurement-to-infusion interval is a critical vulnerability, since patients with rapidly progressive disease may deteriorate and become ineligible during manufacturing.<sup>[10](https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70526)</sup> Toxicity comes almost entirely from the supporting regimen rather than the T cells themselves: high-dose IL-2 causes capillary leak syndrome with hypotension, oliguria, edema, and hypovolemic shock, and in a phase III trial grade 3–4 capillary leak occurred in 30% of patients, all patients developed grade 3–4 neutropenia (median duration 7 days), and grade ≥3 anemia, thrombocytopenia, or febrile neutropenia occurred in 32–82%.<sup>[11](https://pure.amsterdamumc.nl/ws/portalfiles/portal/139845125/Tumour-infiltrating-lymphocyte-therapy-for-patients-with-advanced-stage-melanoma.pdf)</sup> Non-myeloablative chemotherapy also carries long-term marrow risks including myelofibrosis, and it excludes patients with active CNS metastases because of thrombocytopenia and hemorrhage risk.<sup>[12](https://doi.org/10.1016/j.ccell.2024.06.015)</sup> The Amtagvi label carries a Boxed Warning covering prolonged severe cytopenia, severe infection, cardiac disorders, and fatal treatment-related complications.<sup>[2](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma)</sup> Dose-finding data support a toxicity-adapted approach: cyclophosphamide 120 mg/kg added adverse effects without efficacy gains, and the number of post-infusion IL-2 doses was not associated with response in randomized NCI experience.<sup>[10](https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70526)</sup>\n\nCompared with alternatives, TIL therapy is polyclonal, unmodified, and multi-antigen, including neoantigens, which gives low off-tumor toxicity but makes isolating neoantigen-specific lymphocytes difficult and leaves the immunosuppressive tumor microenvironment as an obstacle.<sup>[23](https://www.mdpi.com/2072-6694/14/17/4160)</sup> Against checkpoint inhibitors, the phase III head-to-head comparison with ipilimumab favored TIL on ORR, PFS, and OS.<sup>[4](https://link.springer.com/article/10.1007/s40257-025-00957-5)</sup> Against CAR-T and TCR-engineered cells, TIL targets heterogeneous antigens rather than one chosen antigen.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11005706/)</sup>\n\nRegulatory access remains uneven: [Health Canada](https://www.edgepedia.org/health-canada) conditionally approved lifileucel in August 2025, the marketing authorization application was withdrawn from the EMA in July 2025, and UK decisions are anticipated in 2026.<sup>[7](https://link.springer.com/article/10.1038/s41416-026-03350-z)</sup> NCCN guidelines give a 2A recommendation for considering TIL therapy after progression on anti-PD-1 and, if applicable, BRAF/MEK inhibition, excluding patients with inadequate cardiac, pulmonary, or renal function, or untreated active brain metastases.<sup>[26](https://uhg1-prod.adobecqms.net/content/dam/provider/docs/public/policies/clinical-guidelines/tumor-infiltrating-lymphocyte-cell-therapy.pdf)</sup>\n\n## References\n\n1. [Expert consensus guidelines on management and best practices for TIL cell therapy](https://pmc.ncbi.nlm.nih.gov/articles/PMC11005706/)\n2. [FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma)\n3. [Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC13437784/)\n4. [Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma (Am J Clin Dermatol)](https://link.springer.com/article/10.1007/s40257-025-00957-5)\n5. [Pooled analysis of consecutive cohorts of the C-144-01 study (Chesney et al., J Immunother Cancer 2022)](https://jitc.bmj.com/content/10/12/e005755)\n6. [AMTAGVI (lifileucel) Highlights of Prescribing Information](https://www.fda.gov/media/176417/download)\n7. [Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time? (Br J Cancer)](https://link.springer.com/article/10.1038/s41416-026-03350-z)\n8. [Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Nature Reviews Cancer](https://www.nature.com/articles/nrc2355)\n9. [Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma (Immunity, 2024)](https://doi.org/10.1016/j.immuni.2024.08.014)\n10. [Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions (Cancer, 2026)](https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70526)\n11. [Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma (Klobuch, Seijkens, Schumacher, Haanen)](https://pure.amsterdamumc.nl/ws/portalfiles/portal/139845125/Tumour-infiltrating-lymphocyte-therapy-for-patients-with-advanced-stage-melanoma.pdf)\n12. [Tumor-infiltrating lymphocytes: A new hope (Cancer Cell, 2024)](https://doi.org/10.1016/j.ccell.2024.06.015)\n13. [Steven A. Rosenberg and colleagues (1985). Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer. New England Journal of Medicine.](https://doi.org/10.1056/nejm198512053132327)\n14. [Steven A. Rosenberg, Paul Spiess, Rene Lafreniere (1986). A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes. Science.](https://doi.org/10.1126/science.3489291)\n15. [Steven A. Rosenberg and colleagues (1988). Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. New England Journal of Medicine.](https://doi.org/10.1056/nejm198812223192527)\n16. [Mark E. Dudley and colleagues (2005). Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.2005.00.240)\n17. [Steven A. Rosenberg and colleagues (2011). Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research.](https://doi.org/10.1158/1078-0432.ccr-11-0116)\n18. [Richard A. Morgan and colleagues (2006). Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science.](https://doi.org/10.1126/science.1129003)\n19. [ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors (MDPI Immuno)](https://mdpi-res.com/d_attachment/immuno/immuno-01-00012/article_deploy/immuno-01-00012.pdf?version=1625822468)\n20. [C-144-01 clinical protocol (LN-144 phase 2)](https://cdn.clinicaltrials.gov/large-docs/79/NCT02360579/Prot_000.pdf)\n21. [Amod A. Sarnaik and colleagues (2021). Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.21.00612)\n22. [Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system (Frontiers in Immunology)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1483254/full)\n23. [Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges (Cancers, 2022)](https://www.mdpi.com/2072-6694/14/17/4160)\n24. [Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial (Nature Medicine)](https://pubmed.ncbi.nlm.nih.gov/34385708/)\n25. [Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types (JITC, 2021)](https://jitc.bmj.com/content/jitc/9/10/e003499.full.pdf)\n26. [Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy – Clinical Guideline (UnitedHealthcare)](https://uhg1-prod.adobecqms.net/content/dam/provider/docs/public/policies/clinical-guidelines/tumor-infiltrating-lymphocyte-cell-therapy.pdf)\n27. [Lifileucel First Cellular Therapy Approved for Cancer](https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Biologics, monoclonal antibodies, and biosimilars*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n",
 "same_as": [],
 "url": "https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy",
 "markdown_url": "https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy.md",
 "license": {
  "name": "Edgepedia Community License 1.0",
  "url": "https://www.edgepedia.org/edgepedia/license",
  "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.",
  "spdx": "LicenseRef-Edgepedia-Community-1.0"
 },
 "credit": "\"Tumor-infiltrating lymphocyte therapy\", Edgepedia (EdgeChat), https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy. Edgepedia Community License 1.0.",
 "credit_md": "\"[Tumor-infiltrating lymphocyte therapy](https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy](https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).",
 "credit_html": "\"<a href=\"https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy\">Tumor-infiltrating lymphocyte therapy</a>\", Edgepedia (EdgeChat), <a href=\"https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy\">https://www.edgepedia.org/tumor-infiltrating-lymphocyte-therapy</a>. <a href=\"https://www.edgepedia.org/edgepedia/license\">Edgepedia Community License 1.0</a>.",
 "speakable": "Tumor-infiltrating lymphocyte therapy is an autologous cell therapy for advanced solid cancer in which T cells from a patient's tumor are grown and reinfused."
}